GFRA3

Across TCGA pan-cancer cohorts, GFRA3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GFRA3 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher GFRA3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GFRA3 expression acts as an unfavorable survival marker.

KIRC, OV, and STAD are the cancer types where GFRA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.134	0.811	<.001	30	view →
OV	DFS	Median	All	0.160	0.541	.003	18	view →
STAD	OS	Median	II,III,IV	0.041	0.660	<.001	18	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	11	view →
SARC	DFS	Median	All	0.101	0.632	.011	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GFRA3–KIRC (OS)

Open the KIRC breakdown →